Poor
Mostly Aligned
Patient Risk:
Low
Summary
Only two claims (once-weekly dosing and type 2 diabetes indication) are supported by the provided FDA label excerpts. The majority of claims concern Slovakia pricing/reimbursement and patient assistance, which are absent from the FDA labeling and therefore not auditable against the supplied prescribing information.
Category Scores
Accurate Statements
Mounjaro (tirzepatide) is a once-weekly injectable medication.
11 DESCRIPTION (once weekly; subcutaneous injection)
Mounjaro (tirzepatide) is approved for type 2 diabetes.
1 INDICATIONS AND USAGE (adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus)
Unsupported Statements
The Slovak National Health Service (ŠOP-ÚZ) publishes official drug prices after negotiations with manufacturers.
Not supported by the provided FDA prescribing information (absent from label).
The price for a new drug is usually released around the time the drug is added to the national reimbursement list.
Not supported by the provided FDA prescribing information (absent from label).
In 2026, the price for Mounjaro in Slovakia can be checked in the ŠOP-ÚZ database or on the Ministry of Health website after the reimbursement decision is published.
Not supported by the provided FDA prescribing information (absent from label).
The negotiated list price set by Novo Nordisk is a factor that shapes the price paid in Slovakia for Mounjaro.
Not supported by the provided FDA prescribing information (absent from label).
The drug’s therapeutic value is a factor that shapes the price paid in Slovakia for Mounjaro.
Not supported by the provided FDA prescribing information (absent from label).
Comparative costs of similar treatments are a factor that shapes the price paid in Slovakia for Mounjaro.
Not supported by the provided FDA prescribing information (absent from label).
The budget impact on the national health system is a factor that shapes the price paid in Slovakia for Mounjaro.
Not supported by the provided FDA prescribing information (absent from label).
Once a price is set, insurance schemes determine the co-payment or full coverage for patients.
Not supported by the provided FDA prescribing information (absent from label).
Prices for Mounjaro can shift due to new clinical data, changes in reimbursement status, or renegotiations.
Not supported by the provided FDA prescribing information (absent from label).
In Slovakia, price revisions happen when a drug’s clinical evidence evolves or when budgetary constraints require adjustment.
Not supported by the provided FDA prescribing information (absent from label).
A specific Slovak 2026 price figure is not yet public.
Not supported by the provided FDA prescribing information (absent from label).
European prices for Mounjaro vary widely.
Not supported by the provided FDA prescribing information (absent from label).
In the United Kingdom, the list price is roughly £350 per month for Mounjaro.
Not supported by the provided FDA prescribing information (absent from label).
In Germany, the list price is about €280 per month for Mounjaro.
Not supported by the provided FDA prescribing information (absent from label).
Slovakia typically follows a similar price range to neighboring countries but may set a slightly lower price after negotiations.
Not supported by the provided FDA prescribing information (absent from label).
Exact figures for 2026 will become clear once the national reimbursement decision is published.
Not supported by the provided FDA prescribing information (absent from label).
Novo Nordisk offers a patient assistance program in several countries for Mounjaro.
Not supported by the provided FDA prescribing information (absent from label).
Availability of Novo Nordisk patient assistance in Slovakia depends on local regulations and whether the drug is reimbursed.
Not supported by the provided FDA prescribing information (absent from label).
If the Slovak health system reimburses Mounjaro, patients may pay a small co-payment or none at all depending on the reimbursement category.
Not supported by the provided FDA prescribing information (absent from label).
Non-reimbursed patients typically face the full list price for Mounjaro, which can be several hundred euros per month.
Not supported by the provided FDA prescribing information (absent from label).
The Slovak Ministry of Health, via the ŠOP-ÚZ portal, lists approved drugs along with their reimbursement status and prices.
Not supported by the provided FDA prescribing information (absent from label).
Pharmaceutical companies also post prices on their regional websites, but the ŠOP-ÚZ entry is the authoritative source for official costs.
Not supported by the provided FDA prescribing information (absent from label).
Patients can verify Mounjaro coverage under national health insurance by checking the ŠOP-ÚZ drug catalogue for the drug’s code and reimbursement category.
Not supported by the provided FDA prescribing information (absent from label).
Contradictions
Important Omissions
Details from the FDA label that are not addressed in the provided claims but may be required for safe/complete label-aligned information (e.g., full dosage and administration specifics, contraindications, boxed warnings, warnings/precautions, adverse reactions, monitoring).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided claims contain no FDA-label contraindications, boxed warnings, dosing instructions, or safety monitoring statements. Most claims are about pricing/reimbursement and are not derived from the provided FDA label; no direct label safety conflicts are present within the claim set.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Large portion of statements are absent from the provided FDA prescribing information, so they cannot be audited against the label.
Suggested Improvement
Limit label-based statements to sections supported by the FDA label excerpts (e.g., indication and general once-weekly dosing) and clearly separate non-label information (e.g., Slovakia pricing/reimbursement and patient assistance) from FDA-label-aligned claims.